Search Results for "Nix"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for Nix. Results 1 to 3 of 3 total matches.
See also: pediculicides, permethrin
In Brief: OTC Ivermectin for Head Lice
The Medical Letter on Drugs and Therapeutics • Jun 26, 2023 (Issue 1679)
– generic Widespread 2 months Apply to shampooed, towel-dried hair and 30.00/4 oz2
Nix Permethrin (Insight ...
Topical ivermectin lotion 0.5% (Sklice, and generics),
which has been available by prescription since 2012,
is now FDA-approved for sale over the counter (OTC)
for treatment of head lice in patients ≥6 months old.
Ivermectin is also available by prescription as a 1%
cream (Soolantra) approved for topical treatment of
inflammatory lesions of rosacea and in oral tablets
(Stromectol, and generics) for treatment of various
parasitic infections.
Med Lett Drugs Ther. 2023 Jun 26;65(1679):103-4 doi:10.58347/tml.2023.1679e | Show Introduction Hide Introduction
Drugs for Head Lice
The Medical Letter on Drugs and Therapeutics • Jun 10, 2024 (Issue 1704)
— Permethrin 1% (Nix Permethrin, and
others) is a pyrethroid, a synthetic compound based
on the insecticidal ...
Pediculosis capitis (head lice infestations) occur in
all age groups, but especially in elementary school
children. In most cases, transmission occurs by
head-to-head contact. Pharmacologic treatment is
recommended for persons with live lice or eggs (nits)
within 1 cm of the scalp. Topical pediculicides should
be tried first. Oral therapy is occasionally required for
refractory infestations.
Med Lett Drugs Ther. 2024 Jun 10;66(1704):89-92 doi:10.58347/tml.2024.1704a | Show Introduction Hide Introduction
Drugs for Sexually Transmitted Infections
The Medical Letter on Drugs and Therapeutics • Jun 27, 2022 (Issue 1653)
(pubic lice)
can be transmitted by intimate exposure. Topical
treatment options include permethrin (Nix ...
This article includes recommendations for management
of most sexually transmitted infections (STIs)
other than HIV and viral hepatitis. Some of the
indications and dosages recommended here have
not been approved by the FDA (see Table 1).